Liposomal Encapsulated Rhodomyrtone : A Novel Antiacne Drug

Abstract EN

Rhodomyrtone isolated from the leaves of Rhodomyrtus tomentosa possesses antibacterial, anti-inflammatory, and anti-oxidant activities.

Since rhodomyrtone is insoluble in water, it is rather difficult to get to the target sites in human body.

Liposome exhibited ability to entrap both hydrophilic and hydrophobic compounds and easily penetrate to the target site.

The present study aimed to develop a novel liposomal encapsulated rhodomyrtone formulations.

In addition, characterization of liposome, stability profiles, and their antiacne activity were performed.

Three different formulations of total lipid concentrations 60, 80, and 100 μmol/mL were used.

Formulation with 60 μmol/mL total lipid (phosphatidylcholine from soybean and cholesterol from lanolin in 4 : 1, w/w) exhibited the highest rhodomyrtone encapsulation efficacy (65.47 ± 1.7%), average particle size (209.56 ± 4.8 nm), and ζ-potential (–41.19 ± 1.3 mV).

All formulations demonstrated good stability when stored for 2 months in dark at 4°C as well as room temperature.

Minimal inhibitory concentration and minimal bactericidal concentration values of liposomal formulation against 11 clinical bacterial isolates and reference strains ranged from 1 to 4 and from 4 to 64 μg/mL, respectively, while those of rhodomyrtone were 0.25–1 and 0.5–2 μg/mL, respectively.

The MIC and MBC values of liposome formulation were more effective than topical drugs against Staphylococcus aureus and Staphylococcus epidermidis.